معرفی
Sean Lim is a Professor of Haematology and Translational Immunology at the University of Southampton, funded by a Cancer Research UK Advanced Clinician Scientist Fellowship. His research bridges laboratory and clinical settings, focusing on cancer immunotherapy, monoclonal antibody therapies, and immune responses in lymphoma patients. He leads a research group investigating novel treatments for lymphoma and solid tumors, including CD27 antibody combinations and engineered antibodies. His work has driven clinical trials such as the RiVa study for B-cell malignancies.
Education:
- Medical degree from the University of Bristol (2001)
- PhD in cancer immunology at the University of Southampton (2011)
Research Interests:
- Development of immunostimulatory monoclonal antibodies
- Clinical impact of SARS-CoV-2 vaccination in immunocompromised patients
- Target discovery in peripheral T-cell lymphomas
Publications: Recent work includes high-impact studies on vaccine efficacy in transplant recipients, antibody-based risk prediction for immunocompromised patients, and preclinical CD27 antibody engineering. His research spans Nature Medicine, The Lancet, and Clinical Cancer Research.
Awards:
- BACR Roger Griffin Prize for Cancer Drug Discovery (2018)
- Royal College of Pathologists’ Specialty Research Medal (2012)
Advising & Grants: Supervises five PhD students and leads Cancer Research UK-funded projects. Collaborates with industry partners like BioInvent International AB.
Labs/Teams: Heads the Lim Research Group at the Centre for Cancer Immunology, collaborating with Professors Mark Cragg and Stephen Beers on antibody therapies.
